- Home
- TPST vs DARE Comparison
TPST vs DARE Comparison
Compare TPST & DARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TPST
- DARE
- Stock Information
- Founded
- TPST 2011
- DARE 2015
- Country
- TPST United States
- DARE United States
- Employees
- TPST N/A
- DARE N/A
- Industry
- TPST Biotechnology: Pharmaceutical Preparations
- DARE Biotechnology: Pharmaceutical Preparations
- Sector
- TPST Health Care
- DARE Health Care
- Exchange
- TPST Nasdaq
- DARE Nasdaq
- Market Cap
- TPST 33.0M
- DARE 26.3M
- IPO Year
- TPST N/A
- DARE N/A
- Fundamental
- Price
- TPST $7.50
- DARE $2.41
- Analyst Decision
- TPST Hold
- DARE Strong Buy
- Analyst Count
- TPST 3
- DARE 3
- Target Price
- TPST $30.00
- DARE $12.50
- AVG Volume (30 Days)
- TPST 234.4K
- DARE 39.6K
- Earning Date
- TPST 08-07-2025
- DARE 08-11-2025
- Dividend Yield
- TPST N/A
- DARE N/A
- EPS Growth
- TPST N/A
- DARE N/A
- EPS
- TPST N/A
- DARE N/A
- Revenue
- TPST N/A
- DARE $25,909.00
- Revenue This Year
- TPST N/A
- DARE $99,756.91
- Revenue Next Year
- TPST N/A
- DARE $119.77
- P/E Ratio
- TPST N/A
- DARE N/A
- Revenue Growth
- TPST N/A
- DARE N/A
- 52 Week Low
- TPST $5.35
- DARE $2.35
- 52 Week High
- TPST $30.03
- DARE $4.60
- Technical
- Relative Strength Index (RSI)
- TPST 57.03
- DARE 35.15
- Support Level
- TPST $7.06
- DARE $2.37
- Resistance Level
- TPST $7.18
- DARE $2.54
- Average True Range (ATR)
- TPST 0.27
- DARE 0.11
- MACD
- TPST 0.05
- DARE -0.02
- Stochastic Oscillator
- TPST 86.58
- DARE 17.50
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.
About DARE Dare Bioscience Inc.
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.